Related Experiment Video

Updated: May 8, 2026

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

Antibody-cytokine fusion proteins for cancer immunotherapy: an update on recent developments

Dafne Müller1

  • 1Institute of Cell Biology and Immunology, University of Stuttgart, Allmandring 31, 70569, Stuttgart, Germany, dafne.mueller@izi.uni-stuttgart.de.

Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|September 11, 2013
PubMed

Insights

Antibody-cytokine fusion proteins offer targeted cancer immunotherapy, reducing systemic toxicity. These engineered proteins show promise in preclinical studies and are advancing into clinical trials for improved cancer treatment.

Area of Science:

  • Oncology
  • Immunology
  • Biotechnology

Background:

  • Cytokine therapy is a promising cancer immunotherapy strategy.
  • Systemic toxicity often limits the efficacy of cytokine treatments.
  • Antibody fusion proteins offer a method for tumor-directed delivery of cytokines.

Purpose of the Study:

  • To review recent advancements in antibody-cytokine fusion proteins for cancer immunotherapy.
  • To discuss diverse antibody formats, tumor targets, and cytokine families used.
  • To summarize clinical trial progress and future expectations.

Main Methods:

  • Review of scientific literature on antibody-cytokine fusion proteins.
  • Analysis of preclinical study outcomes.
  • Summary of ongoing clinical evaluations.
  • Discussion of strategies for cytokine modification and presentation.

Main Results:

  • Development of various antibody fusion proteins with promising preclinical therapeutic effects.
  • Several antibody-cytokine fusion protein candidates are currently in clinical evaluation.
  • Diverse antibody formats, tumor targets, and cytokine families are being explored.

Conclusions:

  • Antibody-cytokine fusion proteins are emerging as effective immunologic reagents.
  • These fusion proteins hold significant potential for combinatorial cancer therapies.
  • Further development is expected to enhance their role in cancer treatment.

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...